Skip to main content

Table 1 Variables

From: Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan

Variables Base case Range Distibution Reference
Preemptive skin treatment cost 5324 JPY (48.8 USD) 50% Gammma 11, 14, 15, 16, 17, 18
Treatment cost for skin-toxicity 16,460 JPY (151.0 USD) 50% Gammma 11, 14, 15, 16, 17, 18
Treatment cost for severe skin-toxicity 20,520 JPY (188.3 USD) 50% Gammma 11, 14, 15, 16, 17, 18
Rate of severe skin-toxicity (Preemptive) 0.023 50% Beta 11
Rate of severe skin-toxicity (reactive) 0.114 50% Beta 11
Duration of skin treatment in post-progression state 41 days 95%CI Normal MHLW application for approval
Utility for Progression-free survival state 0.680 30% Beta 20
Utility for Post-progression survival state 0.730 30% Beta 20
Disutility for skin-toxicity 0.033 50% Beta 21, 22, 23, 24
Disutility for severe skin-toxicity 0.100 50% Beta 21, 22, 23, 24
Discount rate 0.02 0–0.04   27
  1. 1 USD = 109.0 JPY (2019 annual exchange rate)